Insmed (INSM) Competitors $144.75 +1.61 (+1.12%) Closing price 04:00 PM EasternExtended Trading$144.75 0.00 (0.00%) As of 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INSM vs. SNY, GSK, TAK, ARGX, ONC, BNTX, TEVA, GMAB, SMMT, and ASNDShould you be buying Insmed stock or one of its competitors? The main competitors of Insmed include Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry. Insmed vs. Its Competitors Sanofi GSK Takeda Pharmaceutical argenex BeOne Medicines BioNTech Teva Pharmaceutical Industries Genmab A/S Summit Therapeutics Ascendis Pharma A/S Sanofi (NASDAQ:SNY) and Insmed (NASDAQ:INSM) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk. Do institutionals & insiders believe in SNY or INSM? 14.0% of Sanofi shares are owned by institutional investors. 1.0% of Sanofi shares are owned by insiders. Comparatively, 3.0% of Insmed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts rate SNY or INSM? Sanofi presently has a consensus target price of $62.67, suggesting a potential upside of 33.73%. Insmed has a consensus target price of $139.86, suggesting a potential downside of 3.38%. Given Sanofi's stronger consensus rating and higher probable upside, analysts plainly believe Sanofi is more favorable than Insmed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sanofi 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 3 Strong Buy rating(s) 3.20Insmed 0 Sell rating(s) 1 Hold rating(s) 16 Buy rating(s) 0 Strong Buy rating(s) 2.94 Which has more risk and volatility, SNY or INSM? Sanofi has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Insmed has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Which has preferable valuation & earnings, SNY or INSM? Sanofi has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSanofi$45.74B2.52$6.02B$4.1611.26Insmed$363.71M84.13-$913.77M-$5.71-25.35 Is SNY or INSM more profitable? Sanofi has a net margin of 21.47% compared to Insmed's net margin of -259.82%. Sanofi's return on equity of 16.86% beat Insmed's return on equity.Company Net Margins Return on Equity Return on Assets Sanofi21.47% 16.86% 9.63% Insmed -259.82%-195.37%-49.49% Does the media refer more to SNY or INSM? In the previous week, Insmed had 7 more articles in the media than Sanofi. MarketBeat recorded 24 mentions for Insmed and 17 mentions for Sanofi. Insmed's average media sentiment score of 1.13 beat Sanofi's score of 0.75 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanofi 8 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 18 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummarySanofi beats Insmed on 11 of the 17 factors compared between the two stocks. Get Insmed News Delivered to You Automatically Sign up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INSM vs. The Competition Export to ExcelMetricInsmedMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.60B$3.08B$5.69B$10.27BDividend YieldN/A2.32%5.72%4.60%P/E Ratio-25.3521.3075.8626.51Price / Sales84.13379.80489.92165.32Price / CashN/A44.4425.8129.89Price / Book90.479.6112.846.32Net Income-$913.77M-$53.28M$3.28B$270.51M7 Day Performance-1.66%0.31%0.22%2.15%1 Month Performance13.26%4.58%4.61%6.35%1 Year Performance97.66%9.24%68.33%25.48% Insmed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INSMInsmed3.3174 of 5 stars$144.75+1.1%$139.86-3.4%+91.7%$30.60B$363.71M-25.351,271Positive NewsInsider TradeSNYSanofi3.9572 of 5 stars$46.80+0.6%$62.67+33.9%-18.4%$114.92B$44.46B11.2582,878GSKGSK2.0072 of 5 stars$40.06-1.1%$37.38-6.7%-6.3%$81.58B$40.10B18.5468,629Positive NewsDividend CutTAKTakeda Pharmaceutical2.4481 of 5 stars$15.27-0.9%N/A+2.6%$48.57B$30.09B50.8847,455High Trading VolumeARGXargenex3.9623 of 5 stars$768.00+2.3%$772.84+0.6%+40.7%$47.00B$2.25B39.381,599Analyst DowngradeONCBeOne Medicines1.7569 of 5 stars$346.45+1.4%$330.89-4.5%N/A$37.97B$3.81B-200.2611,000Gap UpBNTXBioNTech2.5137 of 5 stars$102.66-8.7%$135.80+32.3%-20.7%$24.68B$2.98B-64.166,772High Trading VolumeTEVATeva Pharmaceutical Industries2.7152 of 5 stars$19.30+1.8%$24.71+28.1%+2.7%$22.13B$16.54B-120.6136,830GMABGenmab A/S3.9323 of 5 stars$27.54flat$37.60+36.5%+4.1%$17.67B$3.12B13.842,682Positive NewsSMMTSummit Therapeutics3.3707 of 5 stars$19.44-25.2%$33.79+73.8%-40.7%$14.44B$700K-19.25110Positive NewsAnalyst ForecastHigh Trading VolumeASNDAscendis Pharma A/S2.9554 of 5 stars$205.22-0.3%$244.36+19.1%+63.2%$12.56B$393.54M-39.771,017Positive News Related Companies and Tools Related Companies Sanofi Competitors GSK Competitors Takeda Pharmaceutical Competitors argenex Competitors BeOne Medicines Competitors BioNTech Competitors Teva Pharmaceutical Industries Competitors Genmab A/S Competitors Summit Therapeutics Competitors Ascendis Pharma A/S Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INSM) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersFanatics Hit $31B-Is This Nasdaq Next?Fanatics built an empire by owning the fan experience-scaling to a $31B valuation. But the next wave isn't abo...i2i Marketing Group, LLC | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insmed, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Insmed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INSM Stock Alerts